EUVIMEDEUVIMED entdecken
Crossref

Early LMR Dynamics and AFP Status in Advanced HCC Treated With Atezolizumab/Bevacizumab

Masaki Omori, Shohei Komatsu, Toshifumi Tada, Nobuaki Ishihara, Takanori Matsuura, Eisuke Ueshima, Yoshimi Fujishima, Jun Ishida, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade und 4 weitere

Anticancer Research · 2026

DOI: 10.21873/anticanres.18358 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Masaki Omori und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan. Hauptthemen laut MEDLINE: Liver Neoplasms, alpha-Fetoproteins, Antibodies, Monoclonal, Humanized, Carcinoma, Hepatocellular.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver Neoplasmsalpha-FetoproteinsAntibodies, Monoclonal, HumanizedCarcinoma, HepatocellularBevacizumabMonocytesAntineoplastic Combined Chemotherapy ProtocolsLymphocytesHumansFemaleMaleRetrospective StudiesMiddle AgedAgedAdultBiomarkers, TumorPrognosisTreatment Outcome

Stichwörter der Autor:innen

Hepatocellular carcinomaimmune checkpoint inhibitorlymphocyte-to-monocyte ratio

Substanzen

alpha-FetoproteinsAntibodies, Monoclonal, HumanizedatezolizumabBevacizumabAFP protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan; komasho8@med.kobe-u.ac.jp.
  • Department of Internal Medicine, Division of Gastroenterology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Department of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Division of Oncology, Kobe Minimally invasive Cancer Center, Kobe, Japan.
  • Division of Radiology, Kobe Minimally invasive Cancer Center, Kobe, Japan.

Zitieren

APA

Omori, M., Komatsu, S., Tada, T., Ishihara, N., Matsuura, T., Ueshima, E., Fujishima, Y., Ishida, J., Kido, M., Gon, H., Fukushima, K., Urade, T., Yanagimoto, H., Sofue, K., Kodama, Y., & Fukumoto, T. (2026). Early LMR Dynamics and AFP Status in Advanced HCC Treated With Atezolizumab/Bevacizumab. Anticancer Research. https://doi.org/10.21873/anticanres.18358

Vancouver

Omori M, Komatsu S, Tada T, Ishihara N, Matsuura T, Ueshima E, et al. Early LMR Dynamics and AFP Status in Advanced HCC Treated With Atezolizumab/Bevacizumab. Anticancer Research. 2026. doi:10.21873/anticanres.18358

BibTeX
@article{Omori2026,
  author = {Omori, Masaki and Komatsu, Shohei and Tada, Toshifumi and Ishihara, Nobuaki and Matsuura, Takanori and Ueshima, Eisuke and Fujishima, Yoshimi and Ishida, Jun and Kido, Masahiro and Gon, Hidetoshi and Fukushima, Kenji and Urade, Takeshi and Yanagimoto, Hiroaki and Sofue, Keitaro and Kodama, Yuzo and Fukumoto, Takumi},
  title = {Early LMR Dynamics and AFP Status in Advanced HCC Treated With Atezolizumab/Bevacizumab},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.18358}
}
Kostenlos starten →